[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627791":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":18,"responsibleParty":31,"collaborators":18,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":18,"eligibilityCriteria":40,"healthyVolunteers":36,"sex":41,"minAge":42,"maxAge":18,"enrollmentInfo":43,"targetDuration":18,"studyType":46,"phases":47,"briefSummary":50,"conditions":51,"keywords":18,"overallStatus":53,"whyStopped":18,"lastUpdateSubmitDate":54,"lastUpdatePostDateStruct":55,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":18},{"fullName":5,"class":6},"Assiut University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"patients received empirical dose of RAI","EXPERIMENTAL","patients treated with empirical dose",[13],"Drug: Radioactive Iodine Therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"patients didn't receive empirical dose of RAI","NO_INTERVENTION","patients monitored without empirical RAI dose",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","Radioactive Iodine Therapy","empirical dose of RAI",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Mona Nabil Helbawi","CONTACT","01097040135","monahelbawi561@gmail.com",{"type":32,"investigatorFullName":27,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","principal investigator","100627791","phase-1-empirical-radioactive-iodine-therapy-in-dtc-100627791",false,"NCT07453225","Empirical Radioactive Iodine Therapy in DTC","Efficacy of Empirical Radioactive Iodine Therapy in Differentiated Thyroid Carcinoma Patients With Thyroglobulin Elevation Negative Iodine Scintigraphy (TENIS) Syndrome","Inclusion Criteria:\n\n* This study will include adult patients with pathologically proved DTC who underwent total thyroidectomy and received RAI therapy presented to our nuclear medicine unit with evidence of persistent or recurrent biochemical disease during follow up.\n\nExclusion Criteria:\n\n* Undifferentiated thyroid cancer.\n* Patients with evidence of structural disease.\n* Patients less than 18 years old.","ALL","18 Years",{"count":44,"type":45},100,"ESTIMATED","INTERVENTIONAL",[48,49],"PHASE1","PHASE2","The aim of the study is assessment the efficacy of empiric RAI therapy in DTC patients with elevated thyroglobulin levels and negative iodine scintigraphy.",[52],"Differentiated Thyroid Cancer","NOT_YET_RECRUITING","2026-02-27",{"date":56,"type":57},"2026-03-05","ACTUAL",{"date":59,"type":45},"2026-04-01",{"date":61,"type":45},"2028-07-01",{"name":5,"class":6}]